The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The remarkable impact of mRNA vaccines on mitigating disease and improving public health has been amply demonstrated during the COVID-19 pandemic. Many new mRNA-based vaccine and therapeutic candidates are in development, yet the current reality of their stability limitations requires their frozen storage. Numerous challenges remain to improve formulated mRNA stability and enable refrigerator storage, and this review provides an update on developments to tackle this multi-faceted stability challenge. We describe the chemistry underlying mRNA degradation during storage and highlight how lipid nanoparticle (LNP) formulations are a double-edged sword: while LNPs protect mRNA against enzymatic degradation, interactions with and between LNP excipients introduce additional risks for mRNA degradation. We also discuss strategies to improve mRNA stability both as a drug substance (DS) and a drug product (DP) including the (1) design of the mRNA molecule (nucleotide selection, primary and secondary structures), (2) physical state of the mRNA-LNP complexes, (3) formulation composition and purity of the components, and (4) DS and DP manufacturing processes. Finally, we summarize analytical control strategies to monitor and assure the stability of mRNA-based candidates, and advocate for an integrated analytical and formulation development approach to further improve their storage, transport, and in-use stability profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Self-citationThe clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Li, Y., & Breaker, R. R. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990592p · Cited by 587
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 556
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · cited 7×
“/ Journal of Pharmaceutical Sciences 112 (2023) 386−403 395”
BackgroundInfluentialSelf-citationThe dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498
RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo
Wesselhoeft, R. A., Kowalski, P. S., Parker-Hale, F. C., Huang, Y., Bisaria, N., & Anderson, D. G. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.015 · Cited by 482
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2021) · doi:10.1101/2021.03.29.437587 · Cited by 399
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28776-w · Cited by 399
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Muramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
An Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery
Nogueira, S. S., Schlegel, A., Maxeiner, K., Weber, B., Barz, M., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., et al. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01834 · Cited by 252
Encapsulation state of messenger RNA inside lipid nanoparticles
Brader, M. L., Williams, S. J., Banks, J. M., Hui, W. H., Zhou, Z. H., & Jin, L. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.012 · Cited by 236
Long-term storage of lipid-like nanoparticles for mRNA delivery
Zhao, P., Hou, X., Yan, J., Du, S., Xue, Y., Li, W., Xiang, G., & Dong, Y. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.03.001 · Cited by 233
Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0095-2 · Cited by 206
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Sperberg, R. A. P., Huang, P.-S., Participants, E., & Das, R. (2020) · doi:10.1101/2020.08.22.262931 · Cited by 199
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197
Pollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101262 · Cited by 173
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172
Erasmus, J. H., Khandhar, A. P., Guderian, J., Granger, B., Archer, J., Archer, M., Gage, E., Fuerte-Stone, J., Larson, E., Lin, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.010 · Cited by 161
An efficient method for long-term room temperature storage of RNA
Fabre, A.-L., Colotte, M., Luis, A., Tuffet, S., & Bonnet, J. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.145 · Cited by 151
Structural and molecular mechanisms for the control of eukaryotic 5′–3′ mRNA decay
Mugridge, J. S., Coller, J., & Gross, J. D. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0164-z · Cited by 133
A thermostable messenger RNA based vaccine against rabies
Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., & Petsch, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006108 · Cited by 117
Long-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115
Development of mRNA Vaccines: Scientific and Regulatory Issues
Knezevic, I., Liu, M. A., Peden, K., Zhou, T., & Kang, H.-N. (2021) · Vaccines · doi:10.3390/vaccines9020081 · Cited by 114
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS
Beverly, M., Dell, A., Parmar, P., & Houghton, L. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9605-x · Cited by 83
Kaukinen, U. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.468 · Cited by 69
The effect of secondary structure on cleavage of the phosphodiester bonds of RNA
Mikkola, S., Kaukinen, U., & Lönnberg, H. (2001) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:34:1:95 · Cited by 67
Zhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00861-4 · Cited by 60
Blakney, A. K., Deletic, P., McKay, P. F., Bouton, C. R., Ashford, M., Shattock, R. J., & Sabirsh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.033 · Cited by 48
Polyamines protect nucleic acids against depurination
Terui, Y., Yoshida, T., Sakamoto, A., Saito, D., Oshima, T., Kawazoe, M., Yokoyama, S., Igarashi, K., & Kashiwagi, K. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.04.008 · Cited by 44
Shirane, D., Tanaka, H., Nakai, Y., Yoshioka, H., & Akita, H. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00208 · Cited by 30
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines · doi:10.3390/vaccines10081251 · Cited by 22
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18
Cited by
Research Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 162
“Tris-HCl stabilizes nucleic acid molecules and scavenges hydroxyl radicals [100,101].”
BackgroundExosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
“To address these challenges, innovations are being explored in the fields of formulation and storage [61].”
BackgroundExploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Camperi, J., Roper, B., Freund, E., Leylek, R., Nissenbaum, A., Galan, C., Caothien, R., Hu, Z., Ko, P., Lee, A., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04162 · Cited by 22
Metadata
- Authors
- Oude Blenke, E., Örnskov, E., Schöneich, C., Nilsson, G. A., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 112
- Issue
- 2
- Pages
- 386-403
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W4308293505
- Cited by
- 206
- References
- 47
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.